Akademska digitalna zbirka SLovenije - logo
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • ANGPTL3 Inhibition in Homoz...
    Gaudet, Daniel; Gipe, Daniel A; Pordy, Robert; Ahmad, Zahid; Cuchel, Marina; Shah, Prediman K; Chyu, Kuang-Yuh; Sasiela, William J; Chan, Kuo-Chen; Brisson, Diane; Khoury, Etienne; Banerjee, Poulabi; Gusarova, Viktoria; Gromada, Jesper; Stahl, Neil; Yancopoulos, George D; Hovingh, G. Kees

    New England journal of medicine/˜The œNew England journal of medicine, 07/2017, Letnik: 377, Številka: 3
    Journal Article

    Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.